Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial

被引：18

作者：

Asakura, Masanori ^{[1
,2
]}

Ito, Shin ^{[2
]}

Yamada, Takahisa ^{[3
]}

Saito, Yoshihiko ^{[4
]}

Kimura, Kazuo ^{[5
]}

Yamashina, Akira ^{[6
]}

Hirayama, Atsushi ^{[7
,34
]}

Kobayashi, Youichi ^{[8
]}

Hanatani, Akihisa ^{[9
,34
]}

Tsujimoto, Mitsuru ^{[10
]}

Yasuda, Satoshi ^{[11
]}

Abe, Yukio ^{[12
]}

Higashino, Yorihiko ^{[13
,34
]}

Tamaki, Yodo ^{[14
]}

Sugino, Hiroshi ^{[15
,16
]}

Niinuma, Hiroyuki ^{[17
]}

Okuhara, Yoshitaka ^{[1
]}

Koitabashi, Toshimi ^{[18
]}

Momomura, Shin-Ichi ^{[19
]}

Asai, Kuniya ^{[20
]}

Nomura, Akihiro ^{[21
]}

Kawai, Hiroya ^{[22
,35
]}

Satoh, Yasuhiro ^{[23
]}

Yoshikawa, Tsutomu ^{[24
]}

Hirata, Ken-Ichi ^{[25
]}

Yokoi, Yoshiaki ^{[26
]}

Tanaka, Jun ^{[27
,28
]}

Shibata, Yoshisato ^{[29
]}

Maejima, Yasuhiro ^{[30
]}

Tamaki, Shunsuke ^{[3
]}

Kawata, Hiroyuki ^{[4
,35
]}

Iwahashi, Noriaki ^{[5
]}

Kobayashi, Masatake ^{[6
]}

Higuchi, Yoshiharu ^{[7
,34
]}

Kada, Akiko ^{[31
]}

Yamamoto, Haruko ^{[32
]}

Kitakaze, Masafumi ^{[2
,33
]}

机构：

[1] Hyogo Coll Med, Dept Cardiovasc & Renal Med, Nishinomiya, Hyogo, Japan

[2] Natl Cerebral & Cardiovasc Ctr, Dept Clin Med & Dev, Osaka, Japan

[3] Osaka Gen Med Ctr, Div Cardiol, Osaka, Japan

[4] Nara Med Univ, Nara Med Univ Hosp, Dept Cardiovasc Med, Nara, Japan

[5] Yokohama City Univ, Med Ctr, Div Cardiol, Yokohama, Kanagawa, Japan

[6] Tokyo Med Univ, Dept Cardiol, Tokyo, Japan

[7] Nihon Univ, Itabashi Hosp, Dept Med, Div Cardiol, Tokyo, Japan

[8] Showa Univ Hosp, Dept Med, Div Cardiol, Tokyo, Japan

[9] Osaka City Univ, Grad Sch Med, Dept Cardiovasc Med, Osaka, Japan

[10] Veritas Hosp, Cardiovasc Ctr, Dept Cardiol, Kawanishi, Hyogo, Japan

[11] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan

[12] Osaka City Gen Hosp, Dept Cardiol, Osaka, Japan

[13] Higashi Takarazuka Satoh Hosp, Dept Cardiol, Takarazuka, Hyogo, Japan

[14] Tenri Hosp, Dept Cardiol, Tenri, Nara, Japan

[15] Natl Hosp Org Kure Med Ctr, Dept Cardiac Surg, Hiroshima, Japan

[16] Chugoku Canc Ctr, Hiroshima, Japan

[17] St Lukes Int Hosp, Dept Cardiol, Tokyo, Japan

[18] Kitasato Univ, Sch Med, Dept Cardiovasc Med, Tokyo, Japan

[19] Jichi Med Univ, Saitama Med Ctr, Cardiovasc Div, Saitama, Japan

[20] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Cardiovasc Med, Chiba, Japan

[21] Kanazawa Univ, Grad Sch Med Sci, Dept Cardiovasc & Internal Med, Kanazawa, Ishikawa, Japan

[22] Hyogo Brain & Heart Ctr, Hyogo Prefectural Himeji Cardiovasc Ctr, Div Cardiovasc Med, Himeji, Hyogo, Japan

[23] Natl Hosp Org Disaster Med Ctr, Dept Cardiol, Tokyo, Japan

[24] Sakakibara Heart Inst, Dept Cardiol, Tokyo, Japan

[25] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo, Japan

[26] Kishiwada Tokushukai Hosp, Cardiac Arrhythmia Ctr, Dept Med, Kishiwada, Osaka, Japan

[27] Tokyo Metropolitan Geriatr Hosp, Dept Cardiol, Tokyo, Japan

[28] Inst Gerontol, Tokyo, Japan

[29] Miyazaki Med Assoc Hosp, Dept Cardiol, Miyazaki, Japan

[30] Tokyo Med & Dent Univ, Med Hosp, Dept Cardiovasc Med, Tokyo, Japan

[31] Natl Hosp Org Nagoya Med Ctr, Dept Clin Res Management, Nagoya, Aichi, Japan

[32] Natl Cerebral & Cardiovasc Ctr, Dept Adv Med Technol Dev, 6-1 Kishibeshinmachi, Suita, Osaka 5648565, Japan

[33] Hanwa Daini Senboku Hosp, Naka Ku, 3176 Fukaikitamachi, Sakai, Osaka 5998271, Japan

[34] Osaka Police Hosp, Osaka, Japan

[35] Nara Prefectural Gen Med Ctr, Nara, Japan

来源：

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2022年 / 8卷 / 02期

关键词：

Mineralocorticoid receptor antagonist; Acute heart failure; Eplerenone; ANGIOTENSIN-ALDOSTERONE SYSTEM; MYOCARDIAL-INFARCTION; MORTALITY; HOSPITALIZATION; SPIRONOLACTONE; DYSFUNCTION; GUIDELINES; EMPHASIS; OUTCOMES; BLOCKER;

D O I：

10.1093/ehjcvp/pvaa132

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims A mineralocorticoid receptor antagonist (MRA) is effective in patients with chronic heart failure; however, the effects of the early initiation of an MRA in patients with acute heart failure (AHF) have not been elucidated. Methods and results In this multicentre, randomized, double-blind, placebo-controlled, parallel-group study, we focused on the safety and effectiveness of the treatment with eplerenone, a selective MRA in 300 patients with AHF, that is, 149 in the eplerenone group and 151 in the placebo group in 27 Japanese institutions. The key inclusion criteria were (i) patients aged 20 years or older and (ii) those with left ventricular ejection fraction of <= 40%. The primary outcome was a composite of cardiac death or first re-hospitalization due to cardiovascular disease within 6 months. The mean age of the participants was 66.8 years, 27.3% were women, and the median levels of brain natriuretic peptide were 376.0 pg/mL. The incidences of the primary outcome were 19.5% in the eplerenone group and 17.2% in the placebo group [hazard ratio (HR): 1.09, 95% confidence interval (CI): 0.642-1.855]. In prespecified secondary outcomes, HR for the composite endpoint, cardiovascular death, or first re-hospitalization due to heart failure within 6 months was 0.55 (95% CI: 0.213-1.434). The safety profile for eplerenone was as expected. Conclusion The early initiation of eplerenone in patients with AHF could safely be utilized. The reduction of the incidence of a composite of cardiovascular death or first re-hospitalization for cardiovascular diseases by eplerenone is inconclusive because of inadequate power.

引用

页码：108 / 117

页数：10

共 50 条

[41] THE USE OF KETAMINE FOR ACUTE TREATMENT OF PAIN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Sin, Billy
Tatunchak, Tamara
Paryavi, Mohammad
Olivo, Maria
Mian, Usman
Ruiz, Josel
Shah, Bupendra
de Souza, Sylvie
JOURNAL OF EMERGENCY MEDICINE, 2017, 52 (05): : 601 - 608
[42] The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
McMurray, John J. V.
Freeman, Mason W.
Massaro, Joe
Solomon, Scott
Lock, Paul
Riddle, Matthew C.
Halvorsen, Yuan-Di C.
DIABETES, 2020, 69
[43] Efficacy of melatonin as an adjunct in the treatment of acute mania: a double-blind and placebo-controlled trial
Moghaddam, Hossein Sanjari
Bahmani, Soya
Bayanati, Samaneh
Mahdavinasa, Mahsa
Rezaei, Farzin
Akhondzadeh, Shahin
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2020, 35 (02) : 81 - 88
[44] Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
Machado, Pedro M.
McDermott, Michael P.
Blaettler, Thomas
Sundgreen, Claus
Amato, Anthony A.
Ciafaloni, Emma
Freimer, Miriam
Gibson, Summer B.
Jones, Sarah M.
Levine, Todd D.
Lloyd, Thomas E.
Mozaffar, Tahseen
Shaibani, Aziz, I
Wicklund, Matthew
Rosholm, Anders
Carstensen, Tim Dehli
Bonefeld, Karen
Jorgensen, Anders Norkaer
Phonekeo, Karina
Heim, Andrew J.
Herbelin, Laura
Barohn, Richard J.
Hanna, Michael G.
Dimachkie, Mazen M.
LANCET NEUROLOGY, 2023, 22 (10): : 900 - 911
[45] Double-blind randomized placebo-controlled trial of sibutramine
Bray, GA
Ryan, DH
Gordon, D
Heidingsfelder, S
Cerise, F
Wilson, K
OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
[46] Efficacy and safety of oral niflumic acid in the treatment of acute tendinitis of the limbs (a multicenter, randomized, double-blind, placebo-controlled trial).
Lopez, A
Auguste, P
Maurandy, P
Tamisier, S
Wullaert, P
Martin, C
Lacoste, C
SEMAINE DES HOPITAUX, 1997, 73 (29-30): : 953 - 960
[47] Safety and efficacy of metformin in systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial
Sun, Fangfang
Wang, Hui Jing
Liu, Zhe
Geng, Shikai
Wang, Haiting
Wang, Xiaodong
Li, Ting
Morel, Laurence
Wan, Weiguo
Lu, Liangjing
Teng, Xiangyu
Ye, Shuang
LANCET RHEUMATOLOGY, 2020, 2 (04): : E210 - E216
[48] Multicenter, randomized, double-blind, placebo-controlled, parallel trial comparing the safety and efficacy of rufinamide
Biton, V
Rosenfeld, W
Schachter, S
Perdomo, C
Arroyo, S
ANNALS OF NEUROLOGY, 2005, 58 : S114 - S114
[49] Efficacy and Safety of Vilazodone in Generalized Anxiety Disorder: A Randomized, Double-blind, Placebo-controlled Trial
Thase, Michael E.
Mathews, Maju
Forero, Giovanna
Nunez, Rene
Chen, Changzheng
Gommoll, Carl
Durgam, Suresh
NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S344 - S344
[50] Efficacy and safety of berberine for dyslipidemia: study protocol for a randomized double-blind placebo-controlled trial
Ying Zhao
Yuan-Yuan Yang
Bao-Lin Yang
Ya-Wei Du
Da-Wei Ren
Hong-Mei Zhou
Jing Wang
Hui-Min Yang
Yao-Xian Wang
Ying-Ying Zhang
Sheng-Xian Wu
Trials, 22

← 1 2 3 4 5 →